OABI · OmniAb, Inc.

Current Thesis

OmniAb licenses antibody and ion-channel discovery technology to drug developers and is paid in upfronts, milestones and single-digit royalties on molecules its partners fund and control. The leg an investor buys is that the milestone line has turned from episodic to recurring: Q2 2026 revenue of $13.415M against a $4.693M consensus (reported 2026-08-06), of which $9.515M was license and milestone revenue, followed eleven days later by an Eli Lilly global collaboration for a new ion-channel program carrying an undisclosed upfront and up to $370M in R&D and commercial milestones (2026-08-17).

Two things have happened to the tape since the 2026-08-22 note. It extended — a +8.78% session on 2026-08-24 took the stock to a new 52-week closing high, per SwingTradeBot's signal log, with no company release dated that session — and then it cooled, closing $4.47 on 2026-08-28, 7.1% under the $4.81 52-week high in the adjusted daily series, with RSI(14) at 77.3 against 97.6 on 2026-08-21. The narrative is maturing: both step-change headlines are now weeks old, the only new company release since (2026-08-26) added calendar rather than business, and nothing scheduled forces a fundamental disclosure before the ~November Q3 print.

Bullish and bearish views on OmniAb, Inc.

The model's bull view on OmniAb, Inc. (OABI), in brief: Q2 2026 (2026-08-06): revenue $13.415M vs $4.693M consensus and $3.9M in Q2 2025; EPS -$0.05 vs -$0.12 estimate; net loss narrowed to $5.9M from $15.9M a year earlier. The bear view: Mix quality: $9.515M of the $13.415M Q2 line was license and milestone revenue, which is event-driven. Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-06): revenue $13.415M vs $4.693M consensus and $3.9M in Q2 2025; EPS -$0.05 vs -$0.12 estimate; net loss narrowed to $5.9M from $15.9M a year earlier.
• License and milestone revenue was $9.515M of the Q2 total — the dormant line is now the model.
• FY2026 revenue guidance raised 2026-08-06 to $32–36M from $28–33M, against a $30.807M consensus figure.
• 2026-08-17: Lilly collaboration and license for a new ion-channel program extends paid validation beyond antibodies into the ion-channel screening franchise; same day, year-end 2026 cash guidance was revised to $49–53M from $37–41M, attributed to recent licensing and business-development activity.
• Portfolio KPIs disclosed with Q2 2026: 110 active partners, 425 active programs, 34 clinical-stage or approved, more than 98% of active programs carrying contracted future economics, over $3B of aggregate contracted potential milestones, an average royalty rate near 3.4%, and $340M of remaining contracted potential on programs already in the clinic. Eight of the ten largest pharmaceutical companies are partners.
• Partner funnel events cited with Q2: ramantamig (JNJ-79635322) into Phase 3 in multiple myeloma, a Phase 3 initiation for precemtabart tocentecan in metastatic colorectal cancer, TEV-'408 guided into a Phase 2b vitiligo study in Q4 2026, and IMVT-1402 progressing. OmniAb funds none of these trials.
• 2026-08-26: management confirmed participation at the Nasdaq/LD Micro Summit Series on 2026-09-09 (Nasdaq HQ, San Francisco) and the H.C. Wainwright 28th Annual Global Investment Conference on 2026-09-15 (Lotte New York Palace, New York). The 2026-08-22 read had no confirmed dated event in the window; there are now two.
• H.C. Wainwright reiterated Buy with an $11 price target on 2026-08-17 — the only visible sell-side anchor in the recent record.

Bear Case

• Mix quality: $9.515M of the $13.415M Q2 line was license and milestone revenue, which is event-driven. One deal makes a quarter; the absence of one unmakes the next.
• H1 2026 revenue was $27.8M against a raised full-year guide of $32–36M. Inference, not disclosure: the guide does not underwrite a second half anywhere near the first, consistent with unearned milestones being excluded — and with Q2 being the hardest comparison the stock will face.
• The $370M Lilly figure is contingent milestone potential, not booked revenue, and the upfront was not disclosed. FierceBiotech noted on 2026-08-17 that deal details remained vague.
• Financing capacity sits unused above a doubled price: per the ATM disclosure carried with the Q2 filings, the December 2023 Open Market Sale Agreement with Jefferies (up to $100.0M aggregate) retained roughly $88.3M of unused capacity with no shares sold under it in H1 2026. A loss-making platform with a $49–53M year-end cash target has an obvious use for it.
• Two conference appearances are presentation venues, not disclosure events. Neither 2026-09-09 nor 2026-09-15 obliges new financial or partnership information, so both can pass without changing a single number in the model.
• Retail-facing distribution was heavy at the inflection: gainer-list coverage on 2026-08-07 and pre-market movers coverage on 2026-08-17. That audience arrived at $2–3 closes, not at $4.47.

Setup & Price Structure

The move is documented and steep. Adjusted closes ran $1.96 (2026-08-03), $2.24 (08-06), $3.08 (08-07), a $3.38–$3.43 shelf 08-10 through 08-14, $3.82 (08-17, the Lilly session), $4.33 (08-21), then a +8.78% session on 08-24 to a new 52-week closing high, and $4.47 on 08-28. Three-month price change is +71.3%. The 52-week high in the same series is $4.81, leaving the last close 7.1% beneath it.

What is new structurally is the first genuine cooling: RSI(14) at 77.3 on 2026-08-28 versus 97.6 on 2026-08-21. That is a momentum unwind of about twenty RSI points achieved with only a 7.1% give-back from the high, which is the signature of sideways digestion rather than distribution — though six sessions is far too short a sample to call a base formed. There is no consolidation above the 08-10→08-14 shelf that has lasted more than a few days.

Crowding observables, stated as observables: RSI(14) 77.3 after a 97.6 reading seven sessions earlier; price roughly 30% above the last multi-day shelf at $3.38–$3.43; two unfilled upside gaps beneath (08-06/08-07 earnings, 08-17 Lilly); retail-facing gainer-list coverage clustered on the two event days; $88.3M of untapped ATM capacity per the Q2 filings; two investor conferences inside 30 days; and no insider transaction filings in the public record reviewed for the period since the 2026-08-06 print. The next earnings date is not imminent — that is the shape of this window, not an offset to the momentum reading.

Catalyst Calendar (next 30 days)

• 2026-09-15 — H.C. Wainwright 28th Annual Global Investment Conference, Lotte New York Palace, New York. The house carrying the $11 target hosts it; a fireside there is the most likely source of a refreshed sell-side note inside the window.
• Outside the window, noted: ~2026-11-05 (est.) Q3 2026 results — the first scheduled test of milestone repeatability; and TEV-'408's Phase 2b vitiligo start, guided by Teva for Q4 2026.

Elapsed catalysts

• 2026-09-09 — Nasdaq/LD Micro Summit Series, Nasdaq HQ, San Francisco. Corporate overview plus one-on-one investor meetings (announced 2026-08-26). First scheduled venue for management to frame second-half milestone visibility. (passed 2d ago)
• Undated, any session — partner milestone or new collaboration announcement. The 2026-07-27 VERAXA VXA-222 advancement and the 2026-08-17 Lilly agreement both moved price on the day; with 425 active programs and more than 98% carrying contracted economics, this is the recurring re-rating mechanism and the only one that does not wait for a calendar. (passed 25d ago)

What Would Change Our Mind

Everything above $3.43 was built in two gaps, and the upper one has no traded structure under it. A weekly close below $3.82 would fill the 2026-08-17 Lilly session entirely and leave the $3.38–$3.43 August shelf as the only support beneath — that is the thesis-break condition, and it is the level this note is graded on.

Three non-price conditions would do the same work more slowly. First, 2026-09-09 and 2026-09-15 passing with no new partner agreement and no revision to the $32–36M revenue guide, with price unable to reclaim $4.81 afterwards: at that point the story is fully known and the marginal bid has to come from somewhere new. Second, any registered offering, prospectus supplement or ATM takedown disclosed against the remaining Jefferies capacity — issuance into a doubled price would answer the financing question and reprice the equity in the same move. Third, a Q3 print (~2026-11-05, est.) showing license and milestone revenue below $5M with FY guidance left at $32–36M, which would date the flywheel to two quarters rather than a trend.

The opposite case is narrow and specific: a second undisclosed-upfront collaboration on the Lilly template, or a Q3 guide raise above $36M, would convert the milestone line from a pair of events into a run-rate argument.

Correlation Notes

• Idiosyncratic on event days, beta on the rest. The three sessions that built this move (2026-08-06, 08-07, 08-17) were driven by company releases; between them the stock has traded with small-cap biotech risk appetite. Inference, not disclosure: a broad drawdown in the small-cap biotech complex would carry OABI regardless of deal flow, since nothing in the platform's economics is rate- or index-linked.
• Partner-sponsor read-through is one-directional. OmniAb's royalty value concentrates in assets it neither funds nor controls — ramantamig (J&J), precemtabart tocentecan, TEV-'408 (Teva), IMVT-1402 (Immunovant). A sponsor discontinuation or failed readout is disclosed by the sponsor first and reaches OABI second.
• The closest structural comparison is the royalty-and-milestone aggregator model of former parent Ligand Pharmaceuticals, from which OmniAb separated in late 2022. Both are valued on contracted future economics rather than current earnings, which is why a single deal headline moves the multiple as much as the revenue.
• Eli Lilly's own tape carries no read-through: a $370M contingent milestone package is immaterial to LLY and material to a company guiding $32–36M of full-year revenue.